A growing body of evidence suggests that GLP-1 receptor agonists, a class of medications commonly used to treat diabetes and obesity, may play an important role in managing hidradenitis suppurativa (HS), a chronic and often debilitating skin condition. According to an article published by Healio, dermatologists are now considering these medications as part of a holistic approach to HS care, especially for patients with metabolic risk factors.
Understanding Hidradenitis Suppurativa
HS is a painful, inflammatory skin disorder characterized by recurrent nodules, abscesses, and scarring, typically affecting areas such as the armpits, groin, and under the breasts. The disease can have a profound impact on quality of life, causing significant discomfort, emotional distress, and social isolation. While the exact cause is not fully understood, HS is known to be associated with obesity, metabolic syndrome, and insulin resistance.
Traditional treatments for HS include antibiotics, biologics, and surgical interventions, but many patients experience only partial relief or frequent relapses. As a result, there is ongoing interest in exploring novel therapies that target the underlying metabolic and inflammatory pathways involved in the disease.
GLP-1 Receptor Agonists: A New Avenue
GLP-1 receptor agonists, such as semaglutide and liraglutide, are medications that mimic the action of the natural hormone GLP-1. They have become widely used for type 2 diabetes and weight management due to their ability to promote insulin secretion, reduce appetite, and support weight loss. Recent clinical observations and studies indicate that GLP-1 agonists may also benefit people with HS.
Experts believe that these agents may help control HS in several ways. Weight loss achieved with GLP-1 therapy can reduce skin friction and inflammation, both of which are known to worsen HS symptoms. Additionally, GLP-1 agonists may have direct anti-inflammatory effects, which could further contribute to disease improvement.
Clinical Insights and Recommendations
According to dermatology experts, GLP-1 receptor agonists should be considered for HS patients who have obesity, diabetes, or features of metabolic syndrome—populations at higher risk for severe HS. Early experiences suggest that some patients experience notable reductions in flare-ups and lesion severity after starting GLP-1 therapy.
However, specialists caution that more large-scale, randomized studies are needed to confirm these benefits and determine optimal patient selection. GLP-1 agonists are not a replacement for established HS treatments but may serve as an important adjunct, particularly in patients struggling with both HS and metabolic health issues.
